OpenAI buys Orchestra Bio to build drug-development AI agents

OpenAI's move into pharmaceuticals builds on Rosalind, its life sciences platform that already pairs GPT-Rosalind's biological and chemical analysis with Rosalind Workbench's connection to scientific data and tools. The acquisition adds Orchestra Bio's coordination layer, which the body describes as tracking trials, flagging affected timelines when something goes wrong like a failed production batch, and surfacing options for what to do next.

The stated rationale is that drug development in the US takes ten to 15 years on average, and that beyond scientific hurdles, siloed systems and constant back-and-forth between internal teams and outside partners slow things down. The combined effort aims to build agents that link scientific findings with clinical trials, decisions, and next steps, with the goal of getting new drugs to patients faster.

OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research, suggesting the Orchestra acquisition extends an existing collaboration footprint rather than opening a new one. Financial terms of the deal weren't disclosed.